FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2977193627> ?p ?o ?g. }

• W2977193627 endingPage "75" @default.
• W2977193627 startingPage "67" @default.
• W2977193627 abstract "Dasatinib, a potent Bcr-Abl tyrosine kinase inhibitor, is approved for the treatment of chronic-phase chronic myeloid leukemia (CML-CP) in the frontline and salvage settings. Notable side effects include pleural effusions and myelosuppression. Dasatinib at 50 mg daily has previously been reported to be active and better tolerated than the approved 100-mg daily dose. The aim of this study was to update the long-term follow-up results of dasatinib at 50 mg daily as frontline therapy for CML-CP.Eighty-three patients with newly diagnosed CML-CP received dasatinib at 50 mg daily. Eligibility and response criteria were standards used in previous protocols.After a minimum follow-up of 12 months, 81 patients were evaluable. Two patients came off the study in less than 3 months. The rates of BCR-ABL1 transcript levels (International Standard) at ≤10% and ≤1% at 3 months were 96% and 77%, respectively. The cumulative rates for a complete cytogenetic response by 6 and 12 months were 77% and 95%, respectively. The cumulative rates for a major molecular response, a molecular response with a 4.0-log reduction, and a molecular response with a 4.5-log reduction by 12 months were 81%, 55%, and 49%, respectively. Twenty-one patients (25%) had treatment interruptions for a median of 13 days (range, 4-64 days). Five patients (6%) developed pleural effusions; 4 of these patients (80%) required a dose reduction. Two patients (2%) failed to achieve any cytogenetic or molecular response and were taken off the study. At a median follow-up of 24 months, none of the patients had disease transformation to an accelerated or blastic phase. The 2-year event-free and overall survival rates were 100%.These updated results continue to support 50 mg of dasatinib daily as an effective and safe dose for early CML-CP." @default.
• W2977193627 created "2019-10-03" @default.
• W2977193627 creator A5009582343 @default.
• W2977193627 creator A5013173470 @default.
• W2977193627 creator A5015140142 @default.
• W2977193627 creator A5021380291 @default.
• W2977193627 creator A5028845635 @default.
• W2977193627 creator A5029187559 @default.
• W2977193627 creator A5029247250 @default.
• W2977193627 creator A5035293305 @default.
• W2977193627 creator A5049385583 @default.
• W2977193627 creator A5050041791 @default.
• W2977193627 creator A5051949215 @default.
• W2977193627 creator A5055045706 @default.
• W2977193627 creator A5058755419 @default.
• W2977193627 creator A5070065917 @default.
• W2977193627 creator A5080883357 @default.
• W2977193627 creator A5083793750 @default.
• W2977193627 creator A5084290698 @default.
• W2977193627 creator A5088307376 @default.
• W2977193627 creator A5090435894 @default.
• W2977193627 date "2019-09-25" @default.
• W2977193627 modified "2023-10-17" @default.
• W2977193627 title "Long‐term follow‐up of lower dose dasatinib (50 mg daily) as frontline therapy in newly diagnosed chronic‐phase chronic myeloid leukemia" @default.
• W2977193627 cites W1965429870 @default.
• W2977193627 cites W1968747503 @default.
• W2977193627 cites W1994309500 @default.
• W2977193627 cites W2003973314 @default.
• W2977193627 cites W2040396943 @default.
• W2977193627 cites W2052054991 @default.
• W2977193627 cites W2058216377 @default.
• W2977193627 cites W2085342571 @default.
• W2977193627 cites W2092606584 @default.
• W2977193627 cites W2097799776 @default.
• W2977193627 cites W2097946794 @default.
• W2977193627 cites W2101635775 @default.
• W2977193627 cites W2115626434 @default.
• W2977193627 cites W2119900325 @default.
• W2977193627 cites W2143939343 @default.
• W2977193627 cites W2146658081 @default.
• W2977193627 cites W2160693099 @default.
• W2977193627 cites W2168633862 @default.
• W2977193627 cites W2260921597 @default.
• W2977193627 cites W2314938037 @default.
• W2977193627 cites W2397234997 @default.
• W2977193627 cites W2406641958 @default.
• W2977193627 cites W2516246505 @default.
• W2977193627 cites W2592060299 @default.
• W2977193627 cites W2766187515 @default.
• W2977193627 cites W2801418858 @default.
• W2977193627 cites W2802371729 @default.
• W2977193627 cites W2890138379 @default.
• W2977193627 doi "https://doi.org/10.1002/cncr.32504" @default.
• W2977193627 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8529949" @default.
• W2977193627 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31553487" @default.
• W2977193627 hasPublicationYear "2019" @default.
• W2977193627 type Work @default.
• W2977193627 sameAs 2977193627 @default.
• W2977193627 citedByCount "80" @default.
• W2977193627 countsByYear W29771936272020 @default.
• W2977193627 countsByYear W29771936272021 @default.
• W2977193627 countsByYear W29771936272022 @default.
• W2977193627 countsByYear W29771936272023 @default.
• W2977193627 crossrefType "journal-article" @default.
• W2977193627 hasAuthorship W2977193627A5009582343 @default.
• W2977193627 hasAuthorship W2977193627A5013173470 @default.
• W2977193627 hasAuthorship W2977193627A5015140142 @default.
• W2977193627 hasAuthorship W2977193627A5021380291 @default.
• W2977193627 hasAuthorship W2977193627A5028845635 @default.
• W2977193627 hasAuthorship W2977193627A5029187559 @default.
• W2977193627 hasAuthorship W2977193627A5029247250 @default.
• W2977193627 hasAuthorship W2977193627A5035293305 @default.
• W2977193627 hasAuthorship W2977193627A5049385583 @default.
• W2977193627 hasAuthorship W2977193627A5050041791 @default.
• W2977193627 hasAuthorship W2977193627A5051949215 @default.
• W2977193627 hasAuthorship W2977193627A5055045706 @default.
• W2977193627 hasAuthorship W2977193627A5058755419 @default.
• W2977193627 hasAuthorship W2977193627A5070065917 @default.
• W2977193627 hasAuthorship W2977193627A5080883357 @default.
• W2977193627 hasAuthorship W2977193627A5083793750 @default.
• W2977193627 hasAuthorship W2977193627A5084290698 @default.
• W2977193627 hasAuthorship W2977193627A5088307376 @default.
• W2977193627 hasAuthorship W2977193627A5090435894 @default.
• W2977193627 hasBestOaLocation W29771936271 @default.
• W2977193627 hasConcept C121608353 @default.
• W2977193627 hasConcept C126322002 @default.
• W2977193627 hasConcept C141071460 @default.
• W2977193627 hasConcept C143998085 @default.
• W2977193627 hasConcept C151032500 @default.
• W2977193627 hasConcept C2777583451 @default.
• W2977193627 hasConcept C2778729363 @default.
• W2977193627 hasConcept C2778820342 @default.
• W2977193627 hasConcept C2779536868 @default.
• W2977193627 hasConcept C71924100 @default.
• W2977193627 hasConcept C90924648 @default.
• W2977193627 hasConceptScore W2977193627C121608353 @default.
• W2977193627 hasConceptScore W2977193627C126322002 @default.
• W2977193627 hasConceptScore W2977193627C141071460 @default.

• next